About the ADDA


The Alabama Drug Discovery Alliance (ADDA) is a collaboration between the University of Alabama at Birmingham (UAB) School of Medicine (SOM) and Southern Research Institute (SR), with the UAB Center for Clinical and Translational Science (CCTS) and the UAB Comprehensive Cancer Center (CCC) being crucial contributors to its inception.

CCTS spelled out       

UAB CCC Logo


ADDA's objective is to facilitate drug discovery and development utilizing the resources that exist at the two institutions. These resources include molecular target identification, high through-put screening, three dimensional structure of targets, iterative medicinal chemistry advanced with in silico screening, preclinical toxicology and absorption, distribution, metabolism and excretion (ADME) analysis. Successful compounds for which proof of principle data exist may be advanced into Phase I clinical trials. The ADDA funds pilot projects that are at different stages of the drug discovery and development process, and provides an umbrella of services tailored to the needs of each faculty member and each project.

To stay updated about ADDA activities and funding opportunities, you can This email address is being protected from spambots. You need JavaScript enabled to view it. to be added to ADDA's email distribution list.

Feel free to download a graph depicting our current project pipeline.

For any questions, please contact:

Maaike Everts, PhD
Associate Director - Alabama Drug Discovery Alliance
Associate Professor - School of Medicine
Phone: 205-934-2973
Email: This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it.
Office address:
CHB 309C; 1600 6th Ave S.

Mailing address:
CHB 303; 1600 7th Ave S, Birmingham, AL 35233

uab and sr logo